2 Top Biotech Stocks to Buy Under $10

: CSBR | Champions Oncology, Inc. News, Ratings, and Charts

CSBR – The COVID-19 pandemic brought renewed interest in the biotech industry. Many company’s that weren’t even working on vaccines or treatments saw their shares rise. But there are also great biotech stocks that are not recognized by the market yet. Champions Oncology (CSBR) and Ovid Therapeutics (OVID) are two such stocks that offer strong potential for gains.

There is a common misconception that the vast majority of biotech stocks worthy of investment are priced well above the $10 mark. Some ignore the industry, assuming most of the stocks are traded at several hundred dollars per share. However, if you do your homework, you will find some affordable biotech stocks that can move significantly higher in the near future.

Suppose you have been hesitating to invest in biotech stocks due to the unpredictable nature of the industry or the comparably high price points. In that case, it is time to reassess your strategy. Add a couple of affordable biotech stocks to your portfolio, be patient, and your diversified holdings might work out to your benefit.

Here is a quick look at two biotech stocks priced under $10: Champions Oncology (CSBR) and Ovid Therapeutics (OVID).

Champions Oncology (CSBR)

CSBR develops advanced tech solutions for the personalized development/use of oncology drugs. CSBR has a forward P/E ratio of 47.28. This is an elevated ratio that indicates the stock might be overpriced. 

CSBR has an overall grade of B, translating into a Buy rating in our POWR Ratings system. The stock has a grade of B in the Sentiment and Growth components. CSBR’s Sentiment rank is ahead of more than 90% of all stocks traded on United States markets. Click here to find out how CSBR fares in the rest of the components, including Value, Momentum, Stability, and Quality. 

Of the 494 publicly traded companies in the Biotech industry, CSBR is ranked 16th. You can find other top stocks in this industry by clicking here. Based on the average analyst price target, analysts believe CSBR has more room to run. The average analyst target price for the stock is $15. If CSBR hits this price, it will have increased by nearly 60%. The three analysts that cover the stock rate it a Buy. 

Click here to checkout our Healthcare Sector Report for 2021

Ovid Therapeutics (OVID)

OVID is a biopharmaceutical company that makes therapies for individuals who suffer from rare neurological disorders. The company is currently developing a drug to treat the symptoms of Fragile X syndrome and Angelman syndrome. OVID is also working with Takeda Pharmaceutical (TAK) to develop drugs to treat epileptic encephalopathies.

OVID has an overall grade of B and a Buy rating in our POWR Ratings system. The stock has a grade of A in the Value component and Bs in the Sentiment and Quality components. Click here to find out how OVID fares in the rest of the components, including Momentum, Growth, and Stability. Of the nearly 500 publicly traded companies in the Biotech industry, OVID is ranked 15th. 

Analysts view OVID as undervalued, setting an average target price of $4.88 for the stock. If OVID hits this price target, it will have increased by nearly 24%. Three analysts rate the stock a Strong Buy or Buy.


CSBR shares were unchanged in premarket trading Thursday. Year-to-date, CSBR has declined -13.62%, versus a 17.07% rise in the benchmark S&P 500 index during the same period.


About the Author: Patrick Ryan


Patrick Ryan has more than a dozen years of investing experience with a focus on information technology, consumer and entertainment sectors. In addition to working for StockNews, Patrick has also written for Wealth Authority and Fallon Wealth Management. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
CSBRGet RatingGet RatingGet Rating
OVIDGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


:  |  News, Ratings, and Charts

1 Big Reason Stocks Should Be Soaring Higher

We are entering the heart of earnings season so now is a good time to check in and see how the early reports look and what that means for the stock market outlook (SPY). Spoiler Alert: It looks very bullish. Read on for full details below…

:  |  News, Ratings, and Charts

3 Dividend-Paying Healthcare Stocks Thriving With Lower Rates

Investors should consider adding dividend-paying stocks in the healthcare sector to their portfolios given the drop in rates and rising coronavirus concerns. 3 of the top dividend-paying healthcare stocks are Johnson & Johnson (JNJ), AbbVie Inc. (ABBV), and Unitedhealth Group (UNH).   

:  |  News, Ratings, and Charts

Why Do Most Investors Fail?

Most individual investors underperform the stock market (SPY). Sadly 85% of mutual fund managers also come up short of the mark. So what does work? Quant investing which now makes up more than 50% of daily trading activity. However, these method seem out of reach for most investors. That is all about to change as I will show 5 ways to apply quant investing models to help you beat the market going forward. Read on for more...

:  |  News, Ratings, and Charts

Scathing Allegations Should Make Investors Nervous About Coinbase

Cathie Wood might like Coinbase (COIN) stock, but informed investors should be cautious as a class-action lawsuit pokes holes in Coinbase's reputation.

:  |  News, Ratings, and Charts

Why Do Most Investors Fail?

Most individual investors underperform the stock market (SPY). Sadly 85% of mutual fund managers also come up short of the mark. So what does work? Quant investing which now makes up more than 50% of daily trading activity. However, these method seem out of reach for most investors. That is all about to change as I will show 5 ways to apply quant investing models to help you beat the market going forward. Read on for more...

Read More Stories

More Champions Oncology, Inc. (CSBR) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All CSBR News